Species Differences and Impact of Disease State on BBB

Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs

Volumn , Issue , 2015, Pages 66-93

  Nicolas, Jean Marie ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Blood brain barrier (BBB); Blood CNS interfaces; Central nervous system (CNS); CNS drug disposition; Physiologically based pharmacokinetic (PBPK) modeling

Indexed keywords

ANIMALS; BLOOD; NEUROPHYSIOLOGY; PHARMACOKINETICS;

ANIMAL MODEL; BLOOD-BRAIN BARRIER; BRAIN DISPOSITIONS; CENTRAL NERVOUS SYSTEMS; CNS DRUG DISPOSITION; DISEASE STATE; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS; TRANSLATABILITY;

BRAIN;

EID: 85017382062     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118788523.ch4     Document Type: Chapter

References (201)

1. World Health Organization (WHO). Neurological disorders: public health challenges. WHO: Geneva, 2006; p. xi, 218 pp.
2. Ghose, A. K.; Herbertz, T.; Hudkins, R. L.; Dorsey, B. D.; Mallamo, J. P. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS chemical neuroscience 2012, 3, 50-68.
3. Pangalos, M. N.; Schechter, L. E.; Hurko, O., Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nature reviews. Drug discovery 2007, 6, 521-32.
4. Cummings, J. L.; Banks, S. J.; Gary, R. K.; Kinney, J. W.; Lombardo, J. M.; Walsh, R. R.; Zhong, K., Alzheimer's disease drug development: translational neuroscience strategies. CNS spectrums 2013, 18, 128-38.
5. Pardridge, W. M. Drug transport across the blood-brain barrier. Journal of cerebral blood flow & metabolism 2012, 32, 1959-72.
6. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2, 3-14.
7. Lees, K. R.; Asplund, K.; Carolei, A.; Davis, S. M.; Diener, H. C.; Kaste, M.; Orgogozo, J. M.; Whitehead, J. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 2000, 355, 1949-54.
8. Dawson, D. A.; Wadsworth, G.; Palmer, A. M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain research 2001, 892, 344-50.
9. Markou, A.; Chiamulera, C.; Geyer, M. A.; Tricklebank, M.; Steckler, T. Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 2009, 34, 74-89.
10. Pardridge, W. M. Drug and gene targeting to the brain with molecular Trojan horses. Nature reviews. Drug discovery 2002, 1, 131-9.
11. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of disease 2004, 16, 1-13.
12. Lin, J. H. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Current drug metabolism 2008, 9, 46-59.
13. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry. Current drug metabolism 2006, 7, 183-203.
14. Hammarlund-Udenaes, M.; Friden, M.; Syvanen, S.; Gupta, A. On the rate and extent of drug delivery to the brain. Pharmaceutical research 2008, 25, 1737-50.
15. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development. The journal of pharmacology and experimental therapeutics 2008, 325, 349-56.
16. Deo, A. K.; Theil, F. P.; Nicolas, J. M. Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states. Molecular pharmaceutics 2013, 10, 1581-95.
17. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery. Miniperspective. Journal of medicinal chemistry 2013, 56, 2-12.
18. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept. Chemistry & biodiversity 2009, 6, 2030-49.
19. Fenstermacher, J. D. The blood-brain barrier is not a "barrier" for many drugs. NIDA Research Monographs 1992, 120, 108-20.
20. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. The journal of pharmacology and experimental therapeutics 2005, 313, 1254-62.
21. Paulson, O. B.; Gyory, A.; Hertz, M. M., Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs. Clinical pharmacology & therapeutics 1982, 32, 466-77.
22. Jeffrey, P.; Summerfield, S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiology of disease 2010, 37, 33-7.
23. Westerhout, J.; Danhof, M.; De Lange, E. C. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. Journal of pharmaceutical sciences 2011, 100, 3577-93.
24. Fu, B. M. Experimental methods and transport models for drug delivery across the blood-brain barrier. Current pharmaceutical biotechnology 2012, 13, 1346-59.
25. Soni, V.; Jain, A.; Khare, P.; Gulbake, A.; Jain, S. K. Potential approaches for drug delivery to the brain: past, present, and future. Critical reviews in therapeutic drug carrier systems 2010, 27, 187-236.
26. Pike, V. W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends in pharmacological sciences 2009, 30, 431-40.
27. Jeppsson, F.; Eketjall, S.; Janson, J.; Karlstrom, S.; Gustavsson, S.; Olsson, L. L.; Radesater, A. C.; Ploeger, B.; Cebers, G.; Kolmodin, K.; Swahn, B. M.; von Berg, S.; Bueters, T.; Falting, J. Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. The journal of biological chemistry 2012, 287, 41245-57.
28. Brown, R. P.; Delp, M. D.; Lindstedt, S. L.; Rhomberg, L. R.; Beliles, R. P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicology and industrial health 1997, 13, 407-84.
29. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharmaceutical research 1993, 10, 1093-5.
30. Lei, H.; Pilloud, Y.; Magill, A. W.; Gruetter, R. Continuous arterial spin labeling of mouse cerebral blood flow using an actively-detuned two-coil system at 9.4 T. Conference proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society; 2011 30 Aug-03 Sep; Boston, MA: IEEE Engineering in Medicine and Biology Society. Institute of Electrical and Electronics Engineers (IEEE) Publ.; 2012, pp. 6993-6.
31. Jay, T. M.; Lucignani, G.; Crane, A. M.; Jehle, J.; Sokoloff, L. Measurement of local cerebral blood flow with [14C]iodoantipyrine in the mouse. Journal of cerebral blood flow & metabolism 1988, 8, 121-9.
32. Demchenko, I. T.; Boso, A. E.; Natoli, M. J.; Doar, P. O.; O'Neill, T. J.; Bennett, P. B.; Piantadosi, C. A. Measurement of cerebral blood flow in rats and mice by hydrogen clearance during hyperbaric oxygen exposure. Undersea and hyperbaric medicine 1998, 25, 147-52.
33. Cornford, E. M.; Young, D.; Paxton, J. W.; Sofia, R. D. Blood-brain barrier penetration of felbamate. Epilepsia 1992, 33, 944-54.
34. Bodenheimer, M. M.; Wackers, F. J.; Schwartz, R. G.; Brown, M. Prognostic significance of a fixed thallium defect one to six months after onset of acute myocardial infarction or unstable angina. Multicenter Myocardial Ischemia Research Group. American journal of cardiology 1994, 74, 1196-200.
35. Furuya, Y.; Ikehira, H.; Obata, T.; Koga, M.; Yoshida, K. The measurement of blood flow parameters with deuterium stable isotope MR imaging. Annals of nuclear medicine 1997, 11, 281-4.
36. Weber, B.; Spath, N.; Wyss, M.; Wild, D.; Burger, C.; Stanley, R.; Buck, A. Quantitative cerebral blood flow measurements in the rat using a beta-probe and H2 15O. Journal of cerebral blood flow & metabolism 2003, 23, 1455-60.
37. Otori, T.; Katsumata, T.; Muramatsu, H.; Kashiwagi, F.; Katayama, Y.; Terashi, A. Longterm measurement of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clinical and experimental pharmacology & physiology 2003, 30, 266-72.
38. Moffat, B. A.; Chenevert, T. L.; Hall, D. E.; Rehemtulla, A.; Ross, B. D. Continuous arterial spin labeling using a train of adiabatic inversion pulses. Journal of magnetic resonance imaging 2005, 21, 290-6.
39. Ball, K.; Bouzom, F.; Scherrmann, J. M.; Walther, B.; Decleves, X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone. Journal of pharmaceutical sciences 2012, 101, 4277-92.
40. Karbowski, J. Scaling of brain metabolism and blood flow in relation to capillary and neural scaling. PloS one 2011, 6, e26709.
41. Kassell, N. F.; Baumann, K. W.; Hitchon, P. W.; Gerk, M. K.; Hill, T. R.; Sokoll, M. D. The effects of high dose mannitol on cerebral blood flow in dogs with normal intracranial pressure. Stroke 1982, 13, 59-61.
42. Werner, C.; Kochs, E.; Hoffman, W. E.; Blanc, I. F.; Schulteam Esch, J. Cerebral blood flow and cerebral blood flow velocity during angiotensin-induced arterial hypertension in dogs. Canadian journal of anaesthesia 1993, 40, 755-60.
43. Ito, H.; Kanno, I.; Ibaraki, M.; Hatazawa, J.; Miura, S. Changes in human cerebral blood flow and cerebral blood volume during hypercapnia and hypocapnia measured by positron emission tomography. Journal of cerebral blood flow & metabolism 2003, 23, 665-70.
44. Ito, H.; Kanno, I.; Fukuda, H. Human cerebral circulation: positron emission tomography studies. Annals of nuclear medicine 2005, 19, 65-74.
45. Meltzer, C. C.; Cantwell, M. N.; Greer, P. J.; Ben-Eliezer, D.; Smith, G.; Frank, G.; Kaye, W. H.; Houck, P. R.; Price, J. C. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. Journal of nuclear medicine 2000, 41, 1842-8.
46. Fenstermacher, J.; Nakata, H.; Tajima, A.; Lin, S. Z.; Otsuka, T.; Acuff, V.; Wei, L.; Bereczki, D. Functional variations in parenchymal microvascular systems within the brain. Magnetic resonance in medicine 1991, 19, 217-20.
47. Kumar, G.; Smith, Q. R.; Hokari, M.; Parepally, J.; Duncan, M. W. Brain uptake, phar-macokinetics, and tissue distribution in the rat of neurotoxic N-butylbenzenesulfonamide. Toxicological Sciences 2007, 97, 253-64.
48. Terasaki, T.; Ohtsuki, S.; Hori, S.; Takanaga, H.; Nakashima, E.; Hosoya, K. New approaches to in vitro models of blood-brain barrier drug transport. Drug discovery today 2003, 8, 944-54.
49. Chen, W.; Yang, J. Z.; Andersen, R.; Nielsen, L. H.; Borchardt, R. T. Evaluation of the perme-ation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model. The journal of pharmacology and experimental therapeutics 2002, 303, 849-57.
50. Summerfield, S. G.; Read, K.; Begley, D. J.; Obradovic, T.; Hidalgo, I. J.; Coggon, S.; Lewis, A. V.; Porter, R. A.; Jeffrey, P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. The journal of pharmacology and experimental therapeutics 2007, 322, 205-13.
51. Gross, P. M.; Sposito, N. M.; Pettersen, S. E.; Fenstermacher, J. D. Differences in function and structure of the capillary endothelium in gray matter, white matter and a circumventricular organ of rat brain. Blood vessels 1986, 23, 261-70.
52. Cucullo, L.; Hossain, M.; Rapp, E.; Manders, T.; Marchi, N.; Janigro, D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48, 505-16.
53. Crone, C. The permeability of capillaries in various organs as determined by use of the 'indicator diffusion' method. Actaphysiologica Scandinavica 1963, 58, 292-305.
54. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier. Neurobiology of disease 2010, 37, 13-25.
55. Abraham, M. H. The permeation of neutral molecules, ions, and ionic species through membranes: brain permeation as an example. Journal of pharmaceutical sciences 2011, 100, 1690-701.
56. Murakami, H.; Takanaga, H.; Matsuo, H.; Ohtani, H.; Sawada, Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. American journal of physiology. Heart and circulatory physiology 2000, 279, H1022-8.
57. Kalvass, J. C.; Olson, E. R.; Cassidy, M. P.; Selley, D. E.; Pollack, G. M. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. The journal of pharmacology and experimental therapeutics 2007, 323, 346-55.
58. Wandel, C.; Kim, R.; Wood, M.; Wood, A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 2002, 96, 913-20.
59. Groothuis, D. R.; Levy, R. M. The entry of antiviral and antiretroviral drugs into the central nervous system. Journal of neurovirology 1997, 3, 387-400.
60. Cremer, J. E.; Seville, M. P. Regional brain blood flow, blood volume, and haematocrit values in the adult rat. Journal of cerebral blood flow & metabolism 1983, 3, 254-6.
61. Archer, D. P.; Labrecque, P.; Tyler, J. L.; Meyer, E.; Trop, D. Cerebral blood volume is increased in dogs during administration of nitrous oxide or isoflurane. Anesthesiology 1987, 67, 642-8.
62. Tudorica, A.; Fang Li, H.; Hospod, F.; Delucia-Deranja, E.; Huang, W.; Patlak, C. S.; Newman, G. C. Cerebral blood volume measurements by rapid contrast infusion and T2*-weighted echo planar MRI. Magnetic resonance in medicine 2002, 47, 1145-57.
63. Oshio, K.; Watanabe, H.; Song, Y.; Verkman, A. S.; Manley, G. T. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1. FASEB journal 2005, 19, 76-8.
64. de Lange, E. C. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids and barriers of the CNS 2013, 10, 12.
65. Artru, A. A. Reduction of cerebrospinal fluid pressure by hypocapnia: changes in cerebral blood volume, cerebrospinal fluid volume, and brain tissue water and electrolytes. Journal of cerebral blood flow & metabolism 1987, 7, 471-9.
66. Bergman, I.; Burckart, G. J.; Pohl, C. R.; Venkataramanan, R.; Barmada, M. A.; Griffin, J. A.; Cheung, N. K. Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. The journal of pharmacology and experimental therapeutics 1998, 284, 111-5.
67. Friden, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. Journal of medicinal chemistry 2009, 52, 6233-43.
68. Maurer, M. H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass spectrometry reviews 2010, 29, 17-28.
69. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Journal of pharmaceutical sciences 2002, 91, 129-56.
70. Rodgers, T.; Jones, H. M.; Rowland, M. Tissue lipids and drug distribution: dog versus rat. Journal of pharmaceutical sciences 2012, 101, 4615-26.
71. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. Journal of pharmaceutical sciences 2005, 94, 1259-76.
72. Campbell, S. D.; Regina, K. J.; Kharasch, E. D. Significance of lipid composition in a blood-brain barrier-mimetic PAMPA assay. Journal of biomolecular screening 2014, 19, 437-44.
73. Zhang, Y.; Li, C. S.; Ye, Y.; Johnson, K.; Poe, J.; Johnson, S.; Bobrowski, W.; Garrido, R.; Madhu, C. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo blood-brain barrier permeability. Drug metabolism and disposition 2006, 34, 1935-43.
74. Di, L.; Umland, J. P.; Chang, G.; Huang, Y.; Lin, Z.; Scott, D. O.; Troutman, M. D.; Liston, T. E. Species independence in brain tissue binding using brain homogenates. Drug metabolism and disposition 2011, 39, 1270-7.
75. Read, K. D.; Braggio, S. Assessing brain free fraction in early drug discovery. Expert opinion on drug metabolism & toxicology 2010, 6, 337-44.
76. Tanaka, H.; Mizojiri, K. Drug-protein binding and blood-brain barrier permeability. The journal of pharmacology and experimental therapeutics 1999, 288, 912-8.
77. Bohnert, T.; Gan, L. S. Plasma protein binding: from discovery to development. Journal of pharmaceutical sciences 2013, 102, 2953-94.
78. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. The journal of pharmacology and experimental therapeutics 2006, 316, 1282-90.
79. Jeffrey, P.; Summerfield, S. G. Challenges for blood-brain barrier (BBB) screening. Xenobiotica 2007, 37, 1135-51.
80. Melhem, M. Translation of central nervous system occupancy from animal models: application of pharmacokinetic/pharmacodynamic modeling. The journal of pharmacology and experimental therapeutics 2013, 347, 2-6.
81. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug metabolism and disposition 2007, 35, 660-6.
82. Neuwelt, E. A.; Bauer, B.; Fahlke, C.; Fricker, G.; Iadecola, C.; Janigro, D.; Leybaert, L.; Molnar, Z.; O'Donnell, M. E.; Povlishock, J. T.; Saunders, N. R.; Sharp, F.; Stanimirovic, D.; Watts, R. J.; Drewes, L. R. Engaging neuroscience to advance translational research in brain barrier biology. Nature reviews. Neuroscience 2011, 12, 169-82.
83. Hoshi, Y.; Uchida, Y.; Tachikawa, M.; Inoue, T.; Ohtsuki, S.; Terasaki, T. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. Journal of pharmaceutical sciences 2013, 102, 3343-55.
84. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. Journal of neurochemistry 2011, 117, 333-45.
85. Ito, K.; Uchida, Y.; Ohtsuki, S.; Aizawa, S.; Kawakami, H.; Katsukura, Y.; Kamiie, J.; Terasaki, T. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. Journal of pharmaceutical sciences 2011, 100, 3939-50.
86. Agarwal, S.; Uchida, Y.; Mittapalli, R. K.; Sane, R.; Terasaki, T.; Elmquist, W. F. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug metabolism and disposition 2012, 40, 1164-9.
87. Warren, M. S.; Zerangue, N.; Woodford, K.; Roberts, L. M.; Tate, E. H.; Feng, B.; Li, C.; Feuerstein, T. J.; Gibbs, J.; Smith, B.; de Morais, S. M.; Dower, W. J.; Koller, K. J. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacological research 2009, 59, 404-13.
88. Booth-Genthe, C. L.; Louie, S. W.; Carlini, E. J.; Li, B.; Leake, B. F.; Eisenhandler, R.; Hochman, J. H.; Mei, Q.; Kim, R. B.; Rushmore, T. H.; Yamazaki, M. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse. Journal of pharmacological and toxicological methods 2006, 54, 78-89.
89. Katoh, M.; Suzuyama, N.; Takeuchi, T.; Yoshitomi, S.; Asahi, S.; Yokoi, T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. Journal of pharmaceutical sciences 2006, 95, 2673-83.
90. Takeuchi, T.; Yoshitomi, S.; Higuchi, T.; Ikemoto, K.; Niwa, S.; Ebihara, T.; Katoh, M.; Yokoi, T.; Asahi, S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharmaceutical research 2006, 23, 1460-72.
91. Ohe, T.; Sato, M.; Tanaka, S.; Fujino, N.; Hata, M.; Shibata, Y.; Kanatani, A.; Fukami, T.; Yamazaki, M.; Chiba, M.; Ishii, Y., Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug metabolism and disposition 2003, 31, 1251-4.
92. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Loscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52, 333-46.
93. Syvanen, S.; Lindhe, O.; Palner, M.; Kornum, B. R.; Rahman, O.; Langstrom, B.; Knudsen, G. M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug metabolism and disposition 2009, 37, 635-43.
94. Pike, V. W.; McCarron, J. A.; Lammertsma, A. A.; Osman, S.; Hume, S. P.; Sargent, P. A.; Bench, C. J.; Cliffe, I. A.; Fletcher, A.; Grasby, P. M. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. European journal of pharmacology 1996, 301, R5-7.
95. Zoghbi, S. S.; Liow, J. S.; Yasuno, F.; Hong, J.; Tuan, E.; Lazarova, N.; Gladding, R. L.; Pike, V. W.; Innis, R. B. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. Journal of nuclear medicine 2008, 49, 649-56.
96. Seneca, N.; Zoghbi, S. S.; Liow, J. S.; Kreisl, W.; Herscovitch, P.; Jenko, K.; Gladding, R. L.; Taku, A.; Pike, V. W.; Innis, R. B. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. Journal of nuclear medicine 2009, 50, 807-13.
97. Hsiao, P.; Sasongko, L.; Link, J. M.; Mankoff, D. A.; Muzi, M.; Collier, A. C.; Unadkat, J. D. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. The journal of pharmacology and experimental therapeutics 2006, 317, 704-10.
98. Bauer, M.; Zeitlinger, M.; Karch, R.; Matzneller, P.; Stanek, J.; Jager, W.; Bohmdorfer, M.; Wadsak, W.; Mitterhauser, M.; Bankstahl, J. P.; Loscher, W.; Koepp, M.; Kuntner, C.; Muller, M.; Langer, O. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clinical phar-macology and therapeutics 2012, 91, 227-33.
99. Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang, T.; Eichelbaum, M.; Fromm, M. F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. The journal of pharmacology and experimental therapeutics 2000, 293, 376-82.
100. Syvanen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.; Langstrom, B.; Bergstrom, M.; Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. Journal of pharmaceutical sciences 2008, 97, 5386-400.
101. Liow, J. S.; Lu, S.; McCarron, J. A.; Hong, J.; Musachio, J. L.; Pike, V. W.; Innis, R. B.; Zoghbi, S. S. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse 2007, 61, 96-105.
102. Farwell, M. D.; Chong, D. J.; Iida, Y.; Bae, S. A.; Easwaramoorthy, B.; Ichise, M. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide. Annals of nuclear medicine 2013, 27, 618-24.
103. Yasuno, F.; Zoghbi, S. S.; McCarron, J. A.; Hong, J.; Ichise, M.; Brown, A. K.; Gladding, R. L.; Bacher, J. D.; Pike, V. W.; Innis, R. B. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY. Synapse 2006, 60, 510-20.
104. Liow, J. S.; Kreisl, W.; Zoghbi, S. S.; Lazarova, N.; Seneca, N.; Gladding, R. L.; Taku, A.; Herscovitch, P.; Pike, V. W.; Innis, R. B. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. Journal of nuclear medicine 2009, 50, 108-15.
105. Mairinger, S.; Erker, T.; Muller, M.; Langer, O. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Current drug metabolism 2011, 12, 774-92.
106. Wanek, T.; Kuntner, C.; Bankstahl, J. P.; Mairinger, S.; Bankstahl, M.; Stanek, J.; Sauberer, M.; Filip, T.; Erker, T.; Muller, M.; Loscher, W.; Langer, O. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. Journal of cerebral blood flow & metabolism 2012, 32, 2002-11.
107. Doran, A. C.; Osgood, S. M.; Mancuso, J. Y.; Shaffer, C. L. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations. Drug metabolism and disposition 2012, 40, 2162-73.
108. van Bree, J. B.; Audus, K. L.; Borchardt, R. T. Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharmaceutical research 1988, 5, 369-71.
109. Luckner, P.; Brandsch, M. Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. European journal of pharmaceutics and biopharmaceutics 2005, 59, 17-24.
110. Kamal, M. A.; Keep, R. F.; Smith, D. E. Role and relevance of PEPT2 in drug disposition, dynamics, and toxicity. Drug metabolism and pharmacokinetics 2008, 23, 236-42.
111. Bailey, D. G. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. British journal of clinical pharmacology 2010, 70, 645-55.
112. Lee, W.; Glaeser, H.; Smith, L. H.; Roberts, R. L.; Moeckel, G. W.; Gervasini, G.; Leake, B. F.; Kim, R. B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. The journal of biological chemistry 2005, 280, 9610-7.
113. Li, L.; Agarwal, S.; Elmquist, W. F. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug metabolism and disposition 2013, 41, 659-67.
114. Kielbasa, W.; Stratford, R. E., Jr. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug metabolism and disposition 2012, 40, 877-83.
115. Shawahna, R.; Decleves, X.; Scherrmann, J. M. Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes. Current drug metabolism 2013, 14, 120-36.
116. Miksys, S.; Tyndale, R. F. Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience 2013, 38, 152-63.
117. Ferguson, C. S.; Tyndale, R. F. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in pharmacological sciences 2011, 32, 708-714.
118. Warner, M.; Kohler, C.; Hansson, T.; Gustafsson, J. A. Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. Journal of neurochemistry 1988, 50, 1057-65.
119. Nishimuta, H.; Nakagawa, T.; Nomura, N.; Yabuki, M. Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs. Xenobiotica 2013, 43, 948-55.
120. Stamou, M.; Wu, X.; Kania-Korwel, I.; Lehmler, H. J.; Lein, P. J. Cytochrome P450 mRNA expression in the rodent brain: species-, sex- and region-dependent differences. Drug metabolism and disposition 2013, 42, 239-44.
121. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57, 178-201.
122. Vangilder, R. L.; Rosen, C. L.; Barr, T. L.; Huber, J. D. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacology & Therapeutics 2011, 130, 239-47.
123. Popescu, B. O.; Toescu, E. C.; Popescu, L. M.; Bajenaru, O.; Muresanu, D. F.; Schultzberg, M.; Bogdanovic, N. Blood-brain barrier alterations in ageing and dementia. Journal of the neurological sciences 2009, 283, 99-106.
124. del Zoppo, G. J.; Poeck, K.; Pessin, M. S.; Wolpert, S. M.; Furlan, A. J.; Ferbert, A.; Alberts, M. J.; Zivin, J. A.; Wechsler, L.; Busse, O.; et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Annals of neurology 1992, 32, 78-86.
125. Paul, R.; Lorenzl, S.; Koedel, U.; Sporer, B.; Vogel, U.; Frosch, M.; Pfister, H. W. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Annals of neurology 1998, 44, 592-600.
126. Wolka, A. M.; Huber, J. D.; Davis, T. P. Pain and the blood-brain barrier: obstacles to drug delivery. Advanced Drug Delivery Reviews 2003, 55, 987-1006.
127. Bowman, G. L.; Quinn, J. F. Alzheimer's disease and the blood-brain barrier: past, present and future. Aging health 2008, 4, 47-55.
128. Palmer, J. C.; Baig, S.; Kehoe, P. G.; Love, S. Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. American journal of pathology 2009, 175, 262-270.
129. Dutheil, F.; Jacob, A.; Dauchy, S.; Beaune, P.; Scherrmann, J. M.; Decleves, X.; Loriot, M. A. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders. Expert opinion on drug metabolism & toxicology 2010, 6, 1161-1174.
130. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly nondemented humans. Pharmacogenetics 2002, 12, 535-41.
131. Hartz, A. M.; Miller, D. S.; Bauer, B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Molecular phar-macology 2010, 77, 715-23.
132. Donahue, J. E.; Flaherty, S. L.; Johanson, C. E.; Duncan, J. A., 3rd; Silverberg, G. D.; Miller, M. C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E. G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta neuropathologica 2006, 112, 405-15.
133. Xiong, H.; Callaghan, D.; Jones, A.; Bai, J.; Rasquinha, I.; Smith, C.; Pei, K.; Walker, D.; Lue, L. F.; Stanimirovic, D.; Zhang, W. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. The journal of neuroscience 2009, 29, 5463-75.
134. Westerlund, M.; Belin, A. C.; Olson, L.; Galter, D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients. Cell and tissue research 2008, 334, 179-185.
135. Vautier, S.; Fernandez, C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs. Expert opinion on drug metabolism and toxicology 2009, 5, 1349-1358.
136. Kim, W. S.; Halliday, G. M. Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. Journal of Parkinson's disease 2012, 2, 41-6.
137. Bednarczyk, J.; Lukasiuk, K. Tight junctions in neurological diseases. Acta Neurobiologiae Experimentalis (Wars.) 2011, 71, 393-408.
138. Friedman, A.; Heinemann, U. Role of blood-brain barrier dysfunction in epileptogenesis. In: Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W., Delgado-Escueta, A.V., editors. Jasper's Basic Mechanisms of the Epilepsies. 4th edition (internet). Bethesda: National Center for Biotechnology Information (US); 2012.
139. van Vliet, E. A.; da Costa, A. S.; Redeker, S.; van, S. R.; Aronica, E.; Gorter, J. A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130, 521-34.
140. Marchi, N.; Teng, Q.; Ghosh, C.; Fan, Q.; Nguyen, M. T.; Desai, N. K.; Bawa, H.; Rasmussen, P.; Masaryk, T. K.; Janigro, D. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain research 2010, 1353, 176-86.
141. Appel, S.; Duke, E. S.; Martinez, A. R.; Khan, O. I.; Dustin, I. M.; Reeves-Tyer, P.; Berl, M. B.; Sato, S.; Gaillard, W. D.; Theodore, W. H. Cerebral blood flow and fMRI BOLD auditory language activation in temporal lobe epilepsy. Epilepsia 2012, 53, 631-638.
142. Lazarowski, A.; Czornyj, L.; Lubienieki, F.; Girardi, E.; Vazquez, S.; D'Giano, C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007, 48 Suppl 5, 140-9.
143. Potschka, H. Modulating P-glycoprotein regulation: future perspectives for pharmaco-resistant epilepsies? Epilepsia 2010, 51, 1333-47.
144. van Vliet, E. A.; Redeker, S.; Aronica, E.; Edelbroek, P. M.; Gorter, J. A. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 2005, 46, 1569-80.
145. Ufer, M.; von Stulpnagel, C.; Muhle, H.; Haenisch, S.; Remmler, C.; Majed, A.; Plischke, H.; Stephani, U.; Kluger, G.; Cascorbi, I. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenetics and genomics 2011, 21, 624-30.
146. Ingrisch, M.; Sourbron, S.; Morhard, D.; Ertl-Wagner, B.; Kumpfel, T.; Hohlfeld, R.; Reiser, M.; Glaser, C. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3 T. Investigative radiology 2012, 47, 252-8.
147. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P. O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta 2009, 1788, 842-857.
148. de Vries, H. E.; Kooij, G.; Frenkel, D.; Georgopoulos, S.; Monsonego, A.; Janigro, D. Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia 2012, 53, Suppl 6, 45-52.
149. Kooij, G.; Mizee, M. R.; van Horssen, J.; Reijerkerk, A.; Witte, M. E.; Drexhage, J. A.; van der Pol, S. M.; van Het Hof, B.; Scheffer, G.; Scheper, R.; Dijkstra, C. D.; van der Valk, P.; de Vries, H. E. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis. Brain 2011, 134, 555-70.
150. Muller, N.; Ackenheil, M. Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophrenia research 1995, 14, 223-8.
151. Schwarz, M. J.; Ackenheil, M.; Riedel, M.; Muller, N. Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neuroscience letters 1998, 253, 201-3.
152. Gudmundsson, P.; Skoog, I.; Waern, M.; Blennow, K.; Palsson, S.; Rosengren, L.; Gustafson, D. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. The American journal of geriatric psychiatry 2007, 15, 832-8.
153. Aanerud, J.; Borghammer, P.; Chakravarty, M. M.; Vang, K.; Rodell, A. B.; Jonsdottir, K. Y.; Moller, A.; Ashkanian, M.; Vafaee, M. S.; Iversen, P.; Johannsen, P.; Gjedde, A. Brain energy metabolism and blood flow differences in healthy aging. Journal of cerebral blood flow & metabolism 2012, 32, 1177-87.
154. Farrall, A. J.; Wardlaw, J. M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiology of aging 2009, 30, 337-352.
155. Silverberg, G. D.; Messier, A. A.; Miller, M. C.; Machan, J. T.; Majmudar, S. S.; Stopa, E. G.; Donahue, J. E.; Johanson, C. E. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. Journal of neuropathology and experimental neurology 2010, 69, 1034-43.
156. Nishioku, T.; Furusho, K.; Tomita, A.; Ohishi, H.; Dohgu, S.; Shuto, H.; Yamauchi, A.; Kataoka, Y. Potential role for S100A4 in the disruption of the blood-brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis. Neuroscience 2011, 189, 286-92.
157. Starr, J. M.; Wardlaw, J.; Ferguson, K.; MacLullich, A.; Deary, I. J.; Marshall, I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. Journal of neurology, neurosurgery, and psychiatry 2003, 74, 70-6.
158. Nguyen, J. H. Blood-brain barrier in acute liver failure. Neurochemistry International 2012, 60, 676-83.
159. Cipolla, M. J.; Sweet, J. G.; Chan, S. L. Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia. Journal of Applied Physiology 2011, 110, 329-39.
160. Tang, J. P.; Rakhit, A.; Douglas, F. L.; Melethil, S. Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril. Pharmaceutical research 1992, 9, 236-43.
161. Ong, W. Y.; Halliwell, B. Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage? Annals of the New York Academy of Sciences 2004, 1012, 51-64.
162. Stanimirovic, D. B.; Friedman, A. Pathophysiology of the neurovascular unit: disease cause or consequence? Journal of cerebral blood flow & metabolism 2012, 32, 1207-21.
163. van Assema, D. M.; Lubberink, M.; Bauer, M.; van der Flier, W. M.; Schuit, R. C.; Windhorst, A. D.; Comans, E. F.; Hoetjes, N. J.; Tolboom, N.; Langer, O.; Muller, M.; Scheltens, P.; Lammertsma, A. A.; van Berckel, B. N. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135, 181-9.
164. Bartels, A. L.; van Berckel, B. N.; Lubberink, M.; Luurtsema, G.; Lammertsma, A. A.; Leenders, K. L. Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism & related disorders 2008, 14, 505-8.
165. Bartels, A. L.; Willemsen, A. T.; Kortekaas, R.; de Jong, B. M.; de, V. R.; de, K. O.; van Oostrom, J. C.; Portman, A.; Leenders, K. L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. Journal of Neural Transmission 2008, 115, 1001-1009.
166. Kortekaas, R.; Leenders, K. L.; van Oostrom, J. C.; Vaalburg, W.; Bart, J.; Willemsen, A. T.; Hendrikse, N. H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Annals of neurology 2005, 57, 176-9.
167. Feldmann, M.; Asselin, M. C.; Liu, J.; Wang, S.; McMahon, A.; Anton-Rodriguez, J.; Walker, M.; Symms, M.; Brown, G.; Hinz, R.; Matthews, J.; Bauer, M.; Langer, O.; Thom, M.; Jones, T.; Vollmar, C.; Duncan, J. S.; Sisodiya, S. M.; Koepp, M. J. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet neurology 2013, 12, 777-85.
168. de Klerk, O. L.; Willemsen, A. T.; Bosker, F. J.; Bartels, A. L.; Hendrikse, N. H.; den Boer, J. A.; Dierckx, R. A. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry research 2010, 183, 151-6.
169. de Klerk, O. L.; Willemsen, A. T.; Roosink, M.; Bartels, A. L.; Hendrikse, N. H.; Bosker, F. J.; den Boer, J. A. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. The international journal of neuropsychopharmacology 2009, 12, 895-904.
170. Bauer, M.; Karch, R.; Neumann, F.; Abrahim, A.; Wagner, C. C.; Kletter, K.; Muller, M.; Zeitlinger, M.; Langer, O. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. European journal of clinical pharmacology 2009, 65, 941-6.
171. Bartels, A. L.; Kortekaas, R.; Bart, J.; Willemsen, A. T.; de Klerk, O. L.; de Vries, J. J.; van Oostrom, J. C.; Leenders, K. L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiology of aging 2009, 30, 1818-24.
172. van Assema, D. M.; Lubberink, M.; Boellaard, R.; Schuit, R. C.; Windhorst, A. D.; Scheltens, P.; Lammertsma, A. A.; van Berckel, B. N. P-glycoprotein function at the blood-brain barrier: effects of age and gender. Molecular imaging and biology 2012, 14, 771-6.
173. Toornvliet, R.; van Berckel, B. N.; Luurtsema, G.; Lubberink, M.; Geldof, A. A.; Bosch, T. M.; Oerlemans, R.; Lammertsma, A. A.; Franssen, E. J. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clinical pharmacology and therapeutics 2006, 79, 540-8.
174. Syvanen, S.; Eriksson, J. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS chemical neuroscience 2013, 4, 225-37.
175. Rapposelli, S.; Digiacomo, M.; Balsamo, A. P-gp transporter and its role in neurodegenerative diseases. Current topics in medicinal chemistry 2009, 9, 209-17.
176. Vogelgesang, S.; Glatzel, M.; Walker, L. C.; Kroemer, H. K.; Aguzzi, A.; Warzok, R. W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease. Acta neuropathologica 2006, 111, 436-43.
177. Tishler, D. M.; Weinberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36, 1-6.
178. Loscher, W.; Potschka, H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. The journal of pharmacology and experimental therapeutics 2002, 301, 7-14.
179. Hartz, A. M.; Notenboom, S.; Bauer, B. Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug News & Perspectives 2009, 22, 393-7.
180. Lee, G.; Bendayan, R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharmaceutical research 2004, 21, 1313-30.
181. Drozdzik, M.; Bialecka, M.; Mysliwiec, K.; Honczarenko, K.; Stankiewicz, J.; Sych, Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003, 13, 259-63.
182. Miller, D. S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends in pharmacological sciences 2010, 31, 246-54.
183. Trifiro, G.; Spina, E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Current drug metabolism 2011, 12, 611-20.
184. Watson, P.; Shirreffs, S. M.; Maughan, R. J. Blood-brain barrier integrity may be threatened by exercise in a warm environment. American journal of physiology. Regulatory, integrative and comparative physiology 2005, 288, R1689-94.
185. Spellerberg, B.; Prasad, S.; Cabellos, C.; Burroughs, M.; Cahill, P.; Tuomanen, E. Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides. The Journal of experimental medicine 1995, 182, 1037-43.
186. Spector, R.; Lorenzo, A. V. Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. Journal of clinical investigation 1974, 54, 316-25.
187. Morsing, P.; Adler, G.; Brandt-Eliasson, U.; Karp, L.; Ohlson, K.; Renberg, L.; Sjoquist, P. O.; Abrahamsson, T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999, 33, 1406-13.
188. Hajjar, I.; Brown, L.; Mack, W. J.; Chui, H. Impact of angiotensin receptor blockers on alzheimer disease neuropathology in a large brain autopsy series. Archives of neurology 2012, 1-7.
189. Pelisch, N.; Hosomi, N.; Ueno, M.; Masugata, H.; Murao, K.; Hitomi, H.; Nakano, D.; Kobori, H.; Nishiyama, A.; Kohno, M. Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system. Hypertension research 2010, 33, 161-4.
190. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S. B.; Edison, P.; Hagan, J. J.; Holmes, C.; Jones, E.; Katona, C.; Kearns, I.; Kehoe, P.; Mudher, A.; Passmore, A.; Shepherd, N.; Walsh, F.; Ballard, C. Drug repositioning for Alzheimer's disease. Nature reviews. Drug discovery 2012, 11, 833-46.
191. Fredriksson, K.; Kalimo, H.; Westergren, I.; Kahrstrom, J.; Johansson, B. B. Blood-brain barrier leakage and brain edema in stroke-prone spontaneously hypertensive rats. Effect of chronic sympathectomy and low protein/high salt diet. Acta neuropathologica 1987, 74, 259-68.
192. Lin, K. M.; Chiu, Y. F.; Tsai, I. J.; Chen, C. H.; Shen, W. W.; Liu, S. C.; Lu, S. C.; Liu, C. Y.; Hsiao, M. C.; Tang, H. S.; Liu, S. I.; Chang, L. H.; Wu, C. S.; Tsou, H. H.; Tsai, M. H.; Chen, C. Y.; Wang, S. M.; Kuo, H. W.; Hsu, Y. T.; Liu, Y. L. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenetics and genomics 2011, 21, 163-70.
193. Nikisch, G.; Eap, C. B.; Baumann, P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research 2008, 58, 344-7.
194. Karlsson, L.; Green, H.; Zackrisson, A. L.; Bengtsson, F.; Jakobsen Falk, I.; Carlsson, B.; Ahlner, J.; Kugelberg, F. C. ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. International journal of legal medicine 2013, 127, 579-86.
195. Kim, S. W.; Lee, J. H.; Lee, S. H.; Hong, H. J.; Lee, M. G.; Yook, K. H. ABCB1 c.2677G > T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD. Journal of clinical psychopharmacology 2013, 33, 491-8.
196. Athanasoulia, A. P.; Sievers, C.; Ising, M.; Brockhaus, A. C.; Yassouridis, A.; Stalla, G. K.; Uhr, M. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. European journal of endocrinology 2012, 167, 327-35.
197. Laika, B.; Leucht, S.; Steimer, W., ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clinical chemistry 2006, 52, 893-5.
198. Pauli-Magnus, C.; Feiner, J.; Brett, C.; Lin, E.; Kroetz, D. L. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clinical pharmacology and therapeutics 2003, 74, 487-98.
199. Takano, A.; Kusuhara, H.; Suhara, T.; Ieiri, I.; Morimoto, T.; Lee, Y. J.; Maeda, J.; Ikoma, Y.; Ito, H.; Suzuki, K.; Sugiyama, Y. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil. Journal of nuclear medicine 2006, 47, 1427-33.
200. Kalvass, J. C.; Polli, J. W.; Bourdet, D. L.; Feng, B.; Huang, S. M.; Liu, X.; Smith, Q. R.; Zhang, L. K.; Zamek-Gliszczynski, M. J.; International Transporter C. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clinical pharmacology and therapeutics 2013, 94, 80-94.
201. Uchida, S.; Yamada, S.; Deguchi, Y.; Yamamoto, M.; Kimura, R. In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain. Pharmaceutical research 2000, 17, 844-50.